X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-25 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $83.44 | -71,928 | 106,804 | -40% | -$6,001,932 | |||||
2025-11-25 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale | $80.90 | -4,500 | 787 | -85% | -$364,070 | ||||||
| D | 2025-11-25 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.90 | -5,965 | 5,965 | -50% | -$23,264 | |||||
| D | 2025-11-24 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $80.18 | -35,572 | 106,804 | -25% | -$2,852,031 | |||||
| DM | 2025-11-24 | PTCT | Ptc Therapeutics, Inc. | Jacobson Allan Steven | Dir | S - Sale+OE | $82.00 | -26,000 | 17,451 | -60% | -$2,132,018 | |||||
2025-11-24 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $38.55 | -69,582 | 759,724 | -8% | -$2,682,505 | ||||||
| M | 2025-11-24 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $0.98 | +25,000 | 1,349,289 | +2% | +$24,600 | |||||
2025-11-24 | INSM | Insmed Inc | Anderson Elizabeth M | Dir | S - Sale | $204.58 | -5,000 | 58,729 | -8% | -$1,022,900 | ||||||
| D | 2025-11-24 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $473.65 | -21,000 | 8,142 | -72% | -$9,946,544 | |||||
| D | 2025-11-24 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $473.66 | -22,500 | 2,648 | -89% | -$10,657,280 | |||||
| D | 2025-11-26 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $486.06 | -11,000 | 36,781 | -23% | -$5,346,701 | |||||
2025-11-25 | ADTX | Aditxt, Inc. | Pankovcin Corinne | Chief M, A Officer | S - Sale | $3.20 | -1 | 0 | -100% | -$3 | ||||||
2025-11-24 | NUVL | Nuvalent, Inc. | Shair Matthew | Dir | S - Sale | $109.37 | -7,500 | 1,578,866 | 0% | -$820,274 | ||||||
2025-11-26 | RCUS | Arcus Biosciences, Inc. | Goeltz II Robert C. | CFO | S - Sale | $25.00 | -5,000 | 87,138 | -5% | -$125,000 | ||||||
2025-11-24 | STOK | Stoke Therapeutics, Inc. | Krainer Adrian R. | Dir | S - Sale | $29.72 | -40,472 | 323,774 | -11% | -$1,202,719 | ||||||
| M | 2025-11-24 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $39.97 | +949 | 374,100 | 0% | +$37,933 | |||||
2025-11-24 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $12.04 | -1,878 | 277,860 | -1% | -$22,611 | ||||||
2025-11-24 | OCUL | Ocular Therapeutix, Inc | Dugel Pravin | See Remarks | S - Sale | $12.04 | -19,530 | 3,458,075 | -1% | -$235,141 | ||||||
2025-11-24 | OCUL | Ocular Therapeutix, Inc | Kaiser Peter | Chief Development Officer | S - Sale | $12.02 | -3,007 | 191,433 | -2% | -$36,144 | ||||||
2025-11-24 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Chief Scientific Officer | S - Sale | $12.04 | -3,469 | 245,940 | -1% | -$41,767 | ||||||
| E | 2025-11-25 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.21 | -15,632 | 92,196,978 | 0% | -$3,329 | |||||
| E | 2025-11-25 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.22 | -147,061 | 92,212,610 | 0% | -$32,765 | |||||
2025-11-26 | ABCL | Abcellera Biologics Inc. | Montalbano John S. | Dir | P - Purchase | $3.57 | +50,000 | 226,000 | +28% | +$178,460 | ||||||
| D | 2025-11-24 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.94 | -535 | 0 | -100% | -$2,105 | |||||
2025-11-24 | TTRX | Turn Therapeutics Inc. | Golden Arthur F | Dir | P - Purchase | $3.44 | +9,868 | 60,602 | +19% | +$33,946 | ||||||
| D | 2025-11-25 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale+OE | $54.28 | -1,157 | 18,971 | -6% | -$62,802 | |||||
| D | 2025-11-25 | NKTR | Nektar Therapeutics | Wilson Mark Andrew | GC | S - Sale+OE | $54.28 | -630 | 21,585 | -3% | -$34,196 | |||||
| D | 2025-11-25 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale+OE | $54.28 | -2,207 | 54,273 | -4% | -$119,796 | |||||
2025-11-25 | COCP | Cocrystal Pharma, Inc. | Frost Phillip Md Et Al | Dir, 10% | P - Purchase | $0.94 | +20,000 | 1,726,651 | +1% | +$18,812 | ||||||
| D | 2025-11-25 | AMPH | Amphastar Pharmaceuticals, Inc. | Prins Richard K | Dir | S - Sale+OE | $27.10 | -4,179 | 35,183 | -11% | -$113,253 | |||||
| D | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Rosenberg Noah L. | CMO | P - Purchase | $4.24 | +2,357 | 2,357 | New | +$10,000 | |||||
| D | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Kirby John J. | Interim CFO | P - Purchase | $4.24 | +3,536 | 8,962 | +65% | +$15,001 | |||||
| D | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Zawitz David | COO | P - Purchase | $4.24 | +10,000 | 21,000 | +91% | +$42,425 | |||||
| D | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Rieger Jayson | CEO, Pres | P - Purchase | $4.24 | +94,311 | 183,298 | +106% | +$400,114 | |||||
| D | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $4.24 | +4,126,142 | 7,932,218 | +108% | +$17,505,157 | |||||
| A | 2025-11-24 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $4.08 | +39,200 | 2,753,096 | +1% | +$159,886 | |||||
| DM | 2025-11-21 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.54 | -18,400 | 145,355 | -11% | -$341,074 | |||||
| D | 2025-11-21 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $18.05 | -12,500 | 193,641 | -6% | -$225,588 | |||||
| D | 2025-11-24 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO | S - Sale+OE | $18.86 | -41,163 | 309,892 | -12% | -$776,429 | |||||
| DM | 2025-11-24 | BCAX | Bicara Therapeutics Inc. | Raben David | Chief Medical Officer | S - Sale+OE | $18.65 | -11,000 | 35,497 | -24% | -$205,108 | |||||
| D | 2025-11-24 | ARQT | Arcutis Biotherapeutics, Inc. | Lin Sue-Jean | Dir | S - Sale+OE | $30.78 | -25,272 | 26,735 | -49% | -$777,956 | |||||
2025-11-25 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale | $0.95 | -8,098 | 127,148 | -6% | -$7,696 | ||||||
| M | 2025-11-21 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.92 | -125,576 | 3,287,551 | -4% | -$115,234 | |||||
| M | 2025-11-21 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $0.92 | -195,666 | 5,125,770 | -4% | -$179,551 | |||||
| M | 2025-11-21 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $0.92 | -195,666 | 5,125,770 | -4% | -$179,551 | |||||
| D | 2025-11-21 | VSTM | Verastem, Inc. | Bunn Paul A. | Dir | S - Sale+OE | $10.00 | -6,250 | 8,333 | -43% | -$62,500 | |||||
2025-11-21 | VSTM | Verastem, Inc. | Kauffman Michael | Dir | S - Sale | $10.00 | -8,550 | 8,666 | -50% | -$85,500 | ||||||
| M | 2025-11-21 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $10.00 | -6,000 | 432,818 | -1% | -$60,000 | |||||
2025-11-24 | TGTX | Tg Therapeutics, Inc. | Echelard Yann | Dir | S - Sale | $32.57 | -5,000 | 223,816 | -2% | -$162,850 | ||||||
| D | 2025-11-21 | PTCT | Ptc Therapeutics, Inc. | Reeve Emma | Dir | S - Sale+OE | $79.50 | -10,000 | 6,666 | -60% | -$795,000 | |||||
2025-11-21 | TYRA | Tyra Biosciences, Inc. | More Robert J | Dir | S - Sale | $20.25 | -246,871 | 3,833,425 | -6% | -$5,000,026 | ||||||
| DM | 2025-11-24 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $473.05 | -8,000 | 644,489 | -1% | -$3,784,419 | |||||
2025-11-21 | ARDX | Ardelyx, Inc. | Grammer Elizabeth A | See Remarks | S - Sale | $5.54 | -5,995 | 299,895 | -2% | -$33,194 | ||||||
2025-11-21 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $5.54 | -46,887 | 1,480,727 | -3% | -$259,609 | ||||||
2025-11-21 | ARDX | Ardelyx, Inc. | Kelliher Mike | See Remarks | S - Sale | $5.54 | -5,560 | 271,181 | -2% | -$30,785 | ||||||
2025-11-21 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Patient Officer | S - Sale | $5.54 | -6,426 | 359,896 | -2% | -$35,580 | ||||||
2025-11-21 | ARDX | Ardelyx, Inc. | Foster Eric Duane | Chief Commercial Officer | S - Sale | $5.54 | -5,814 | 295,684 | -2% | -$32,192 | ||||||
2025-11-21 | ARDX | Ardelyx, Inc. | Reilly Joseph James | See Remarks | S - Sale | $5.54 | -11,086 | 108,914 | -9% | -$61,382 | ||||||
2025-11-25 | ABT | Abbott Laboratories | Shroff Eric | SVP | S - Sale | $128.02 | -1,586 | 30,384 | -5% | -$203,043 | ||||||
| M | 2025-11-21 | MAIA | Maia Biotechnology, Inc. | Vitoc Vlad | CEO, 10% | P - Purchase | $0.98 | +11,800 | 1,031,021 | +1% | +$11,547 | |||||
2025-11-21 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale | $19.78 | -14,328 | 27,737 | -34% | -$283,408 | ||||||
| D | 2025-11-21 | MIRM | Mirum Pharmaceuticals, Inc. | Grey Michael G | Dir | S - Sale+OE | $70.00 | -50,000 | 280,160 | -15% | -$3,500,000 | |||||
2025-11-21 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | CFO | S - Sale | $35.00 | -3,427 | 0 | -100% | -$119,945 | ||||||
2025-11-24 | SAVA | Cassava Sciences Inc | Anderson Robert Eugene Jr | Dir | P - Purchase | $2.90 | +8,600 | 8,600 | New | +$24,940 | ||||||
2025-11-21 | VERA | Vera Therapeutics, Inc. | Carter Jason S | GC | S - Sale | $27.82 | -3,864 | 49,136 | -7% | -$107,498 | ||||||
2025-11-21 | ALMS | Alumis Inc. | Foresite Capital Management VI LLC | 10% | P - Purchase | $7.38 | +72,212 | 15,778,040 | 0% | +$532,925 | ||||||
2025-11-21 | ALMS | Alumis Inc. | Tananbaum James B. | Dir, 10% | P - Purchase | $7.38 | +72,212 | 15,778,040 | 0% | +$532,925 | ||||||
2025-11-21 | ALMS | Alumis Inc. | Foresite Labs, LLC | 10% | P - Purchase | $7.38 | +72,212 | 15,778,040 | 0% | +$532,925 | ||||||
| E | 2025-11-24 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.05 | -142,307 | 92,359,671 | 0% | -$6,426 | |||||
| M | 2025-11-21 | CVRX | Cvrx, Inc. | Johnson & Johnson | 10% | S - Sale | $10.05 | -2,700 | 4,047,198 | 0% | -$27,132 | |||||
2025-11-24 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $4.08 | +39,200 | 2,743,096 | +1% | +$159,886 | ||||||
| M | 2025-11-21 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | Pres, 10% | P - Purchase | $6.16 | +30,000 | 10,494,140 | 0% | +$184,660 | |||||
2025-11-24 | NUVL | Nuvalent, Inc. | Flynn James E | Director by Deputization, 10% | S - Sale | $95.45 | -742,574 | 17,248,450 | -4% | -$70,874,975 | ||||||
2025-11-20 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $7.20 | +125,743 | 5,134,991 | +3% | +$905,350 | ||||||
2025-11-20 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $65.84 | -26,156 | 5,622,909 | 0% | -$1,722,224 | ||||||
| M | 2025-11-21 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $30.35 | -50,000 | 973,671 | -5% | -$1,517,405 | |||||
| D | 2025-11-24 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $17.07 | -37,600 | 50,897 | -42% | -$641,697 | |||||
| M | 2025-11-21 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $0.80 | +22,000 | 756,460 | +3% | +$17,600 | |||||
| D | 2025-11-20 | JAZZ | Jazz Pharmaceuticals Plc | McSharry Heather Ann | Dir | S - Sale+OE | $177.78 | -3,415 | 20,449 | -14% | -$607,127 | |||||
2025-11-20 | NTHI | Neonc Technologies Holdings, Inc. | Neman-Ebrahim Yousha | Chief Clinical Officer | P - Purchase | $6.69 | +1,100 | 134,260 | +1% | +$7,359 | ||||||
| M | 2025-11-20 | SION | Sionna Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $39.61 | -30,316 | 159,033 | -16% | -$1,200,704 | |||||
2025-11-20 | SLRX | Salarius Pharmaceuticals, Inc. | Hanish Arnold C | Dir | P - Purchase | $0.75 | +5,000 | 5,027 | >999% | +$3,741 | ||||||
2025-11-20 | GRTX | Galera Therapeutics, Inc. | Sorensen Mel | Pres, CEO | S - Sale | $0.02 | -70,000 | 195,029 | -26% | -$1,407 | ||||||
2025-11-21 | TRDA | Entrada Therapeutics, Inc. | Wentworth Kory James | CFO | S - Sale | $9.98 | -8,910 | 110,026 | -7% | -$88,932 | ||||||
| D | 2025-11-20 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $105.00 | -3,350 | 20,814 | -14% | -$351,750 | |||||
2025-11-20 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $41.76 | -3,520 | 63,000 | -5% | -$147,002 | ||||||
2025-11-20 | TRDA | Entrada Therapeutics, Inc. | Baker Bros. Advisors LP | 10% | P - Purchase | $9.07 | +28,867 | 4,691,392 | +1% | +$261,846 | ||||||
| D | 2025-11-20 | NUVB | Nuvation Bio Inc. | Hattersley Gary | Chief Scientific Officer | S - Sale+OE | $7.23 | -369,051 | 0 | -100% | -$2,667,132 | |||||
| D | 2025-11-20 | NUVB | Nuvation Bio Inc. | Liu Dongfang | CHIEF MEDICAL OFFICER | S - Sale+OE | $7.00 | -20,000 | 18,000 | -53% | -$140,074 | |||||
| D | 2025-11-20 | REGN | Regeneron Pharmaceuticals, Inc. | Bassler Bonnie L | Dir | S - Sale+OE | $750.00 | -760 | 1,548 | -33% | -$570,000 | |||||
| D | 2025-11-20 | TEVA | Teva Pharmaceutical Industries Ltd | Fox Christine | EVP, Head of U.S. Commercial | S - Sale+OE | $24.78 | -28,229 | 63,647 | -31% | -$699,523 | |||||
2025-11-20 | SAVA | Cassava Sciences Inc | Barry Richard | Pres, CEO | P - Purchase | $2.76 | +150,000 | 938,060 | +19% | +$414,000 | ||||||
| E | 2025-11-21 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.17 | -105,326 | 92,501,978 | 0% | -$17,994 | |||||
2025-11-21 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $1.14 | +5,000 | 281,421 | +2% | +$5,700 | ||||||
2025-11-21 | TTRX | Turn Therapeutics Inc. | Golden Arthur F | Dir | P - Purchase | $2.87 | +20,532 | 50,734 | +68% | +$58,927 | ||||||
| M | 2025-11-20 | ANNX | Annexon, Inc. | Satter Muneer A | Dir | P - Purchase | $4.38 | +822,613 | 9,728,637 | +9% | +$3,600,784 | |||||
| D | 2025-11-20 | PRAX | Praxis Precision Medicines, Inc. | Nemiroff Alex | GC, Secretary | S - Sale+OE | $193.09 | -25,130 | 20,832 | -55% | -$4,852,256 | |||||
| D | 2025-11-20 | PRAX | Praxis Precision Medicines, Inc. | Mastrocola Lauren | Principal Accounting Officer | S - Sale+OE | $192.08 | -13,600 | 10,442 | -57% | -$2,612,244 | |||||
2025-11-19 | ROIV | Roivant Sciences Ltd. | Manchester Keith S | Dir | S - Sale | $20.23 | -1,300,000 | 18,047,727 | -7% | -$26,304,500 | ||||||
2025-11-19 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Dir | S - Sale | $20.23 | -1,300,000 | 18,047,727 | -7% | -$26,304,500 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |